Trials / Terminated
TerminatedNCT00410930
Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients
Double-Blind Placebo-Controlled Study of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (planned)
- Sponsor
- Stallergenes Greer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
To compare versus placebo the efficacy and safety of recombinant Bet v1, natural purified Bet v1 and birch pollen licenced extract used for subcutaneous immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Subcutaneous immunotherapy - Recombinant birch pollen |
Timeline
- Start date
- 2002-11-01
- Completion
- 2005-11-01
- First posted
- 2006-12-13
- Last updated
- 2006-12-19
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00410930. Inclusion in this directory is not an endorsement.